NEWTON, Mass.--(BUSINESS WIRE)-- Clinical Data, Inc. (NASDAQ: CLDA) today announced that Drew Fromkin, President and Chief Executive Officer, will be presenting a corporate overview at the 13th Annual BIO CEO & Investor Conference. Clinical Data's presentation will take place at 9:00 a.m. EST on Tuesday, February 15, 2011 at The Waldorf-Astoria in New York, NY.
A live and archived audio webcast of the Company’s presentation can be accessed through Clinical Data's website at www.clda.com.
About Clinical Data, Inc.
Clinical Data's mission is to develop first-in-class and best-in-category therapeutics. The Company’s lead product, Viibryd, was approved for marketing by the FDA for the treatment of major depressive disorder in adults. The Company is also advancing its late-stage drug candidate, Stedivaze, a pharmacologic stress agent in Phase III development for use during myocardial perfusion imaging. Clinical Data has promising drug candidates entering the clinic in major therapeutic areas including asthma, ophthalmology and diabetes. To learn more, please visit the Company's website at www.clda.com.
Clinical Data, Inc.
Theresa McNeely, 617-467-6673
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials FDA